Carboplatin + Docetaxel + Pembrolizumab + Pegfilgrastim
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer
Trial Timeline
Sep 4, 2018 → Nov 1, 2024
NCT ID
NCT03639948About Carboplatin + Docetaxel + Pembrolizumab + Pegfilgrastim
Carboplatin + Docetaxel + Pembrolizumab + Pegfilgrastim is a phase 2 stage product being developed by Merck for Triple-negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03639948. Target conditions include Triple-negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03639948 | Phase 2 | Active |
Competing Products
20 competing products in Triple-negative Breast Cancer